Unlock instant, AI-driven research and patent intelligence for your innovation.

Methods and compositions for improving outcome in cancer patients

A composition and cancer technology, which can be used in drug combinations, active ingredients of heterocyclic compounds, pharmaceutical formulations, etc., can solve problems such as aggravating tumor vascularization and impairing aerobic metabolism.

Pending Publication Date: 2022-03-22
雷文知识产权控股有限公司
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Insufficient oxygen delivery impairs aerobic metabolism and exacerbates tumor vascularization

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compositions for improving outcome in cancer patients
  • Methods and compositions for improving outcome in cancer patients
  • Methods and compositions for improving outcome in cancer patients

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0282] The role of the composition of the present invention in recovery after chemotherapy

[0283] In this example, the compositions of the invention as disclosed herein are developed as intravenous (IV) drug therapy with the ability to correct underlying perfusion defects and correct intracellular electrolytes and metabolism associated with critical limb ischemia (CLI). Unusual Potential ( Image 6 ).

[0284] The composition of the present invention (also referred to in this study as "RJX") contains an acid-base chemical component capable of causing an acidic blood flow pH shift followed by an alkaline rebound, similar to aerobic exercise, but without concurrent Oxygen debt incurred. These components may also have the potential to cause metabolic advantages. The compositions of the present invention also provide a concentration of magnesium to the bloodstream that can act with acid-base chemistry to rebalance "levels" of ionic species within cells. The compositions of...

Embodiment 2

[0391] Effects of the compositions of the invention as shown in horses suffering from Mallem's disease, Cushing's disease or laminitis

[0392] In this example, the compositions of the invention as disclosed herein are formulated as intravenous (IV) drug therapy with the ability to correct underlying perfusion defects and intracellular electrolyte and metabolic abnormalities associated with critical limb ischemia (CLI) potential. The compositions of the present invention contain acid-base chemical components that cause an acidic bloodstream pH shift followed by an alkaline rebound, similar to aerobic exercise, but without incurring concomitant oxygen debt. These components may also have the potential to cause metabolic advantages. The compositions of the present invention provide increased concentrations of magnesium to the bloodstream, which can act with acid-base chemistry to rebalance "levels" of intracellular ionic species. It results in a decrease in intracellular cal...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure provides compositions and methods for improving outcome in cancer patients. Specifically, the present disclosure provides a method of preventing, alleviating, or treating cancer comprising administering to a subject in need thereof an effective amount of a composition wherein the composition comprises a sterile aqueous solution of at least one drug-grade acid and at least one drug-grade pH buffer wherein when administered to the subject, the at least one drug-grade pH buffer is at least one of the at least one drug-grade acid and the at least one drug-grade pH buffer is at least one of the at least one drug-grade acid and the at least one drug-grade pH buffer. The concentration of the drug-grade acid and the drug-grade pH buffer in the buffer solution is sufficient to provide a total titratable acid content of 60 mmol / L to 3000 mmol / L, and wherein the drug-grade acid and the drug-grade pH buffer are selected to provide a buffer solution pH of 4.0 to 7.7.

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS [0002] This application claims the benefit of priority to US Provisional Application 62 / 860,642, filed June 12, 2019, the entire disclosure of which is incorporated herein by reference in its entirety. technical field [0003] The present invention generally relates to methods of improving outcomes in cancer patients by administering compositions as disclosed herein. Background technique [0004] Homeostasis is the ability of an organism to maintain a state of equilibrium or steady state within its internal environment, especially when faced with external changes. Some examples of homeostatic control systems in humans include regulation of constant body temperature, blood glucose levels, and concentrations of extracellular ionic species. Acid-base homeostasis involves the proper balance of acids and bases in the extracellular fluid, ie the pH of the extracellular fluid. In humans, the pH of plasma is approximately 7.4 and is...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/185A61K31/19A61K33/10A61P35/00
CPCA61P7/00A61K31/714A61K31/375A61K33/00A61K31/4415A61K31/675A61K31/455A61K31/51A61P3/10A61P3/12A61K31/16A61K33/06A61P3/14A61K33/20A61K31/19A61K47/02A61P35/00
Inventor J.埃尔文H.J.P.范维克B.D.德诺姆M.L.范维克P.帕库尔特M.A.沃克N.M.皮齐门蒂P.B.兰格
Owner 雷文知识产权控股有限公司